Assessment Of Health Technology Appraisals To Identify Key Drivers For Reimbursement Of Oncology Drugs With Only Phase 2 Clinical Data

Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.414
https://www.valueinhealthjournal.com/article/S1098-3015(17)30748-9/fulltext
Section Title : Disease-Specific Studies
Section Order : 389
First Page : A471
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30748-9&doi=10.1016/j.jval.2017.08.414
HEOR Topics :
Tags :
Regions :